中国医师杂志
中國醫師雜誌
중국의사잡지
JOURNAL OF CHINESE PHYSICIAN
2012年
10期
1331-1334
,共4页
俞富军%郑建建%高申孟%董培红
俞富軍%鄭建建%高申孟%董培紅
유부군%정건건%고신맹%동배홍
鱼精蛋白类/遗传学%重组融合蛋白质类/遗传学%微RNAs%肝硬化
魚精蛋白類/遺傳學%重組融閤蛋白質類/遺傳學%微RNAs%肝硬化
어정단백류/유전학%중조융합단백질류/유전학%미RNAs%간경화
Protamines/genetics%Recombinant fusion Proteins/genetics%MicroRNAs%Liver cirrhosis
目的 观察TGF-βⅡR单链抗体/轻链恒定区/鱼精蛋白截短体融合蛋白(简称新型载体)携带miR-29b对体外培养肝星状细胞(HSC)的转染效率和治疗效果,为今后肝纤维化基因治疗提供新载体.方法 脂质体、新型载体和慢病毒携带miR-29b治疗体外培养的HSC,荧光显微镜和流式细胞术观察转染效率,实时荧光定量RT-PCR和Western Blot技术分析collagen α(1) (Ⅰ) mRNA和蛋白表达水平.结果 与对照组比较,慢病毒组的转染效率最高,为70%;其次为新型载体组,为58%;最后为脂质体组,为29%.各载体组collagen α1(Ⅰ) mRNA表现出不同的下降,与对照组比较,慢病毒组下降70%(t=6.316,P<0.01),新型载体组为50%(t=4.082,P<0.01),脂质体组为38%(t =3.014,P<0.05).各载体组collagen α1 (Ⅰ)蛋白也表现出不同的下降,慢病毒组下降为59%(t=4.209,P<0.01);新型载体组为41%(t =4.033,P<0.01;);脂质体组为27%(f=2.842,P<0.05).结论 笔者构建的新型载体具有较高的转染效率,并且携带miR-29b具有较好的抗肝纤维化效果.
目的 觀察TGF-βⅡR單鏈抗體/輕鏈恆定區/魚精蛋白截短體融閤蛋白(簡稱新型載體)攜帶miR-29b對體外培養肝星狀細胞(HSC)的轉染效率和治療效果,為今後肝纖維化基因治療提供新載體.方法 脂質體、新型載體和慢病毒攜帶miR-29b治療體外培養的HSC,熒光顯微鏡和流式細胞術觀察轉染效率,實時熒光定量RT-PCR和Western Blot技術分析collagen α(1) (Ⅰ) mRNA和蛋白錶達水平.結果 與對照組比較,慢病毒組的轉染效率最高,為70%;其次為新型載體組,為58%;最後為脂質體組,為29%.各載體組collagen α1(Ⅰ) mRNA錶現齣不同的下降,與對照組比較,慢病毒組下降70%(t=6.316,P<0.01),新型載體組為50%(t=4.082,P<0.01),脂質體組為38%(t =3.014,P<0.05).各載體組collagen α1 (Ⅰ)蛋白也錶現齣不同的下降,慢病毒組下降為59%(t=4.209,P<0.01);新型載體組為41%(t =4.033,P<0.01;);脂質體組為27%(f=2.842,P<0.05).結論 筆者構建的新型載體具有較高的轉染效率,併且攜帶miR-29b具有較好的抗肝纖維化效果.
목적 관찰TGF-βⅡR단련항체/경련항정구/어정단백절단체융합단백(간칭신형재체)휴대miR-29b대체외배양간성상세포(HSC)적전염효솔화치료효과,위금후간섬유화기인치료제공신재체.방법 지질체、신형재체화만병독휴대miR-29b치료체외배양적HSC,형광현미경화류식세포술관찰전염효솔,실시형광정량RT-PCR화Western Blot기술분석collagen α(1) (Ⅰ) mRNA화단백표체수평.결과 여대조조비교,만병독조적전염효솔최고,위70%;기차위신형재체조,위58%;최후위지질체조,위29%.각재체조collagen α1(Ⅰ) mRNA표현출불동적하강,여대조조비교,만병독조하강70%(t=6.316,P<0.01),신형재체조위50%(t=4.082,P<0.01),지질체조위38%(t =3.014,P<0.05).각재체조collagen α1 (Ⅰ)단백야표현출불동적하강,만병독조하강위59%(t=4.209,P<0.01);신형재체조위41%(t =4.033,P<0.01;);지질체조위27%(f=2.842,P<0.05).결론 필자구건적신형재체구유교고적전염효솔,병차휴대miR-29b구유교호적항간섬유화효과.
Objective To observe the transfection efficiency and anti-fibrotic effect of miR-29b transfected by anti-TGF-β Ⅱ R ScFv/Ck/tP fusion protein (new vector) in hepatic stellate cell (HSC),and to provide a new vector in gene therapy for liver fibrosis.Methods The liposome vector,new vector,and lentiviral vector were used as transfection reagents to transfect miR-29b into HSC.Transfection efficiency was observed under fluorescence microscope and flow cytometry.Collagen α1 (Ⅰ) mRNA and protein expression in different groups were analyzed by real-time RT-PCR and Western Blot,respectively.Results Compared to the control,transfection efficiencies in lentiviral vector,new vector,and liposome vector groups were about 70%,58%,and 29%,respectively.Collagen α1 (Ⅰ) mRNA expression in lentiviral vector,new vector,and liposome vector groups was decreased by about 70%,50%,and 38%,respectively ((t =6.316,P <0.01 ; t =4.082,P <0.01 ; t =3.014,P <0.05).Collagen α1(Ⅰ) protein expression in lentiviral vector,new vector,and liposome vector groups was decreased by about 59%,41%,and 27%,respectively (t =4.209,P <0.01; t =4.033,P <0.01; t =2.842,P <0.05).Conclusions The new vector constructed by us has a high transfection efficiency.MiR-29b transfected by the new vector has a good anti-liver fibrosis effect.